G Parmiani

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Natl Cancer Inst 94:805-18. 2002
  2. ncbi T-cell response to unique and shared antigens and vaccination of cancer patients
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Immun 2:6. 2002
  3. ncbi Unique human tumor antigens: immunobiology and use in clinical trials
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori Foundation, Milan, Italy
    J Immunol 178:1975-9. 2007
  4. ncbi Melanoma antigens and their recognition by T cells
    G Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian, 1 20133 Milano, Italy
    Keio J Med 50:86-90. 2001
  5. ncbi Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal
    G Parmiani
    Gene Therapy Program, Istituto Nazionale Tumori, Milan, Italy
    Hum Gene Ther 11:1269-75. 2000
  6. ncbi Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens
    C Castelli
    Division of Experimental Oncology D, Istituto Nazionale Tunori, Milan, Italy
    J Immunol 162:1739-48. 1999
  7. ncbi Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability
    A Anichini
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 46:508-15. 1990
  8. ncbi Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients
    C Castelli
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Eur J Immunol 28:1143-54. 1998
  9. ncbi A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients
    N Cascinelli
    Division of Surgical Oncology B, Istituto Nazionale Tumori, Milano, Italy
    Tumori 75:233-44. 1989
  10. ncbi Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low f
    R Mortarini
    Division of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 57:5534-41. 1997

Detail Information

Publications104 found, 100 shown here

  1. ncbi Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Natl Cancer Inst 94:805-18. 2002
    ....
  2. ncbi T-cell response to unique and shared antigens and vaccination of cancer patients
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Immun 2:6. 2002
    ..Thus, it is likely that the subgroup of metastatic patients with a high frequency of anti-melanoma memory T cells may not show a clinical response to vaccination...
  3. ncbi Unique human tumor antigens: immunobiology and use in clinical trials
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori Foundation, Milan, Italy
    J Immunol 178:1975-9. 2007
    ....
  4. ncbi Melanoma antigens and their recognition by T cells
    G Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian, 1 20133 Milano, Italy
    Keio J Med 50:86-90. 2001
    ..This response, however, appears unable to effectively counteract metastatic melanoma growth...
  5. ncbi Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal
    G Parmiani
    Gene Therapy Program, Istituto Nazionale Tumori, Milan, Italy
    Hum Gene Ther 11:1269-75. 2000
    ....
  6. ncbi Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens
    C Castelli
    Division of Experimental Oncology D, Istituto Nazionale Tunori, Milan, Italy
    J Immunol 162:1739-48. 1999
    ....
  7. ncbi Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability
    A Anichini
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 46:508-15. 1990
    ....
  8. ncbi Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients
    C Castelli
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Eur J Immunol 28:1143-54. 1998
    ....
  9. ncbi A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients
    N Cascinelli
    Division of Surgical Oncology B, Istituto Nazionale Tumori, Milano, Italy
    Tumori 75:233-44. 1989
    ....
  10. ncbi Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low f
    R Mortarini
    Division of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 57:5534-41. 1997
    ..These results suggest that CD34+- and monocyte-derived DCs are not functionally equivalent APCs for the activation of low-frequency peptide-specific CTLps...
  11. ncbi Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes
    A Mazzocchi
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Immunol Immunother 50:199-211. 2001
    ..Thus, B7-IL2 gene-transduced melanoma lines appear to display a high immunogenicity and could be used as vaccine in melanoma patients...
  12. ncbi Human dendritic cells: natural adjuvants in antitumor immunotherapy
    M Di Nicola
    Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Cytokines Cell Mol Ther 4:265-73. 1998
    ....
  13. ncbi An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in m
    A Anichini
    Department of Experimental Oncology Human Tumor Immunobiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy
    J Exp Med 190:651-67. 1999
    ....
  14. ncbi Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells
    C Castelli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 61:222-7. 2001
    ....
  15. ncbi Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones
    M Sensi
    Unit of Human Tumor Immunobiology, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tissue Antigens 59:273-9. 2002
    ..In conclusion, the identification of the HTMEVTVYHR peptide will extend to HLA-A*6801 melanoma patients the possibility to exploit gp100/pMel17 melanosomal protein for experimental and clinical studies...
  16. ncbi Multipeptide vaccination in cancer patients
    Lorenzo Pilla
    Immuno biotherapy of Melanoma and Solid Tumors, San Raffaele Foundation Scientific Institute, Milan, Italy
    Expert Opin Biol Ther 9:1043-55. 2009
    ..With the ultimate goal of combining peptide selection with patient-specific immunogenic profile, peptide based anti-cancer vaccines remain a promising treatment for cancer patients, as attested by of pre-clinical and clinical studies...
  17. ncbi Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization
    P Pisarra
    Human Tumors Immunobiology, Department of Experimental Oncology, National Cancer Institute, Milan, Italy
    J Invest Dermatol 115:48-56. 2000
    ..The pattern of expression of these isoforms suggest that they might play a part in the normal pathway of melanin biosynthesis...
  18. ncbi Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells
    G Pietra
    Unit of Human Tumors Immunobiology, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Res 61:8218-26. 2001
    ..These results suggest a novel mechanism of tumor escape that may prevent the development of antitumor immunity through the maturation block induced in DCs by neoplastic cells in the early phase of apoptosis...
  19. ncbi Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression
    I Martin-Padura
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Cancer Res 51:2239-41. 1991
    ..These data demonstrate intratumor heterogeneity in the expression of VLA-4 and that this can represent a crucial determinant of tumor cell interaction with EC during secondary spread...
  20. ncbi Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins
    R Mortarini
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 47:551-9. 1991
    ..These data indicate that constitutive heterogeneity in the integrin profile or cytokine-mediated shifts in VLA expression can affect the ability of human melanoma cells to interact with different ECM components...
  21. ncbi Cancer vaccination
    M del Vecchio
    Unit of Immunotherapy of Human Tumours, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Forum (Genova) 9:239-56. 1999
    ..This review will briefly focus on the biological basis of the development and the clinical application of a wide spectrum of tumour vaccines...
  22. ncbi Retroviral heterogeneity in mouse lymphomas
    M P Colombo
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Oncogene 2:395-8. 1988
    ..The possibility that retroviruses can induce the expression of novel histocompatibility antigens on tumors is discussed...
  23. ncbi Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy
    M Rodolfo
    Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    Cancer Gene Ther 8:491-6. 2001
    ..Our results suggest that systemic, liposome-mediated administration of genes coding for antiangiogenic factors represents a promising strategy for melanoma treatment in humans...
  24. ncbi Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer
    N Jonjic
    Istituto di Ricerche Farmacologiche, Mario Negri, Milan, Italy
    Eur J Immunol 22:2255-60. 1992
    ....
  25. ncbi Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers
    C Gambacorti-Passerini
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Clin Cancer Res 3:675-83. 1997
    ..These data provide the first list of peptides derived from fusion proteins that may be assessed as potential tumor-specific antigens...
  26. ncbi Tumour-released exosomes and their implications in cancer immunity
    M Iero
    Unit of Immunotherapy of Human Tumours, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, Milan, Italy
    Cell Death Differ 15:80-8. 2008
    ..Hence, their secretion by neoplastic cells may in the future become a novel pathway to target for therapeutic intervention in cancer patients...
  27. ncbi Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
    G Parmiani
    Unit of Immunotherapy of Human Tumors, Department of Innovative Therapies, Istituto Nazionale Tumori, Milan, Italy
    Ann Oncol 18:226-32. 2007
    ..The potential mechanisms of the GM-CSF-mediated immune suppression are discussed at the light of studies describing the activation and expansion of myeloid suppressor cells by endogenous tumor-derived or exogenous GM-CSF...
  28. ncbi A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancer
    C Gambacorti-Passerini
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italia
    Tumori 74:523-30. 1988
    ..With this procedure therefore large quantities of lymphokine activated killer cells (LAK) can be easily produced to be used in adoptive immunotherapy trials...
  29. ncbi Beta 1-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones
    A Anichini
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    J Immunother (1991) 12:183-6. 1992
    ..These data indicate that expression of some beta 1-integrins on human melanoma can influence the specific and nonspecific T-cell-mediated recognition of neoplastic cells...
  30. ncbi Genes involved in melanoma: an overview of INK4a and other loci
    M Castellano
    Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Melanoma Res 9:421-32. 1999
    ..Melanoma is a well-characterized disease in terms of its progression stages; therefore obtaining precise genetic information is crucial in the development of a stepwise model of melanoma pathogenesis...
  31. ncbi P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines
    G Capranico
    Division of Experimental Oncology B, Istituto Nazionale Tumori, Milan, Italy
    Br J Cancer 59:682-5. 1989
    ..These results, suggesting that different genetic mechanisms could be responsible for P-glycoprotein overexpression, emphasise the complexity of genetic regulation that may affect tumour cell sensitivity to cytotoxic agents...
  32. ncbi Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody
    C Melani
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 58:4146-54. 1998
    ....
  33. ncbi HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins
    C Bertazzoli
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Tumori 83:847-55. 1997
    ..Further optimization of culture conditions, type of Antigen Presenting Cells (APC), peptides, use of stabilizers like beta 2-m are still needed...
  34. ncbi Vaccination of patients with solid tumours
    G Parmiani
    Unit of Immunotherapy of Human Tumours, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 14:817-24. 2003
    ..Possible means of overcoming the clinical limits and improving the outcome of previous studies are also discussed...
  35. ncbi Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
    M Sensi
    Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Oncogene 25:3357-64. 2006
    ..Moreover, the presence of NRASQ61R or BRAFV600E is associated with distinct in vitro and in vivo growth properties of neoplastic cells...
  36. ncbi Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2
    M Squadrelli-Saraceno
    Head and Neck Surgical Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Tumori 76:566-71. 1990
    ..No relevant side effects occurred. These results indicate that loco-regional immunotherapy with rIL-2 and LAK cells can produce clinical responses in advanced head and neck cancer patients...
  37. ncbi Loss of heterozygosity of DQ alpha gene in human malignant melanoma
    C Castelli
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Tumori 75:378-82. 1989
    ....
  38. ncbi Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study
    G Pizzocaro
    Division of Urology, Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Clin Oncol 19:425-31. 2001
    ..Overall and event-free survival were to be evaluated together with prognostic factors...
  39. ncbi Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line
    R Supino
    Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
    Br J Cancer 57:142-6. 1988
    ..The results are consistent with the view that anthracycline resistance may be multifactorial and probably arises following multiple biochemical changes...
  40. ncbi CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation
    G Della Torre
    Department of Experimental Oncology, Istituto Nazionale Tumori, Via Venezian, 1 20133 Milan, Italy
    Br J Cancer 85:836-44. 2001
    ..In addition, they indicate the need for a combination of functional assays to determine the pathogenetic nature of new CDKN2A mutations...
  41. ncbi Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients
    S Spinazze
    Division of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Tumori 77:496-9. 1991
    ..This suggests that the interleukin-2-induced cortisol rise has no relevant clinical importance in antagonizing the activation of an effective antitumor immune response during cancer immunotherapy with interleukin-2...
  42. ncbi A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects
    R Marolda
    Division of Surgical Oncology "B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 73:575-84. 1987
    ..Other dose-related toxicities were thrombocytopenia and malaise. All side effects disappeared 2-3 days after the end of rIL2 administration. No major responses were seen in association with the 4-8 days of treatment given in this study...
  43. ncbi Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
    R Lupetti
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    J Exp Med 188:1005-16. 1998
    ....
  44. ncbi A TaqI RFLP at the gas-2 locus
    M P Colombo
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy
    Nucleic Acids Res 17:7545. 1989
  45. ncbi Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1)
    M Vagliani
    Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Immunogenetics 38:157-60. 1993
  46. ncbi Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:3942-9. 2005
    ..Altogether, these findings identify the activation of the NK compartment as an additional immunologic effect of autologous tumor-derived HSP96 administration in cancer patients...
  47. ncbi Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes
    Roberta Valenti
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:9290-8. 2006
    ..Therapeutic interventions on the crucial steps of this pathway may contribute to restore tumor/immune system interactions favoring T-cell-mediated control of tumor growth in cancer patients...
  48. ncbi Vaccination: role in metastatic melanoma
    Lorenzo Pilla
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Unit of Immunotherapy of Human Tumors, Via Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 6:1305-18. 2006
    ....
  49. ncbi Heat shock proteins gp96 as immunogens in cancer patients
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Int J Hyperthermia 22:223-7. 2006
    ....
  50. ncbi Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors
    Tiziana Di Pucchio
    Section of Experimental Immunotherapy, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit, Rome, Italy
    Cancer Res 66:4943-51. 2006
    ....
  51. ncbi Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity
    Chiara Casati
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:4450-60. 2006
    ....
  52. ncbi Chemokine receptor 7, a new player in regulating apoptosis of CD8+ T cells in cancer patients
    Giorgio Parmiani
    Clin Cancer Res 11:7587-8. 2005
  53. ncbi A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 55:958-68. 2006
    ..Clinical activity was limited to SD. However, both immunological and clinical responses were not improved as compared with those recorded in a previous study investigating HSPPC-96 monotherapy...
  54. ncbi Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape
    Veronica Huber
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Gastroenterology 128:1796-804. 2005
    ..This mechanism of immune escape has potential implications as a prognostic factor and could be targeted for the development of new antitumor therapies in colorectal cancer patients...
  55. ncbi Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
    Licia Rivoltini
    Istituto Nazionale Tumori, ViaVenezian 1, 20133 Milan, Italy
    Expert Opin Biol Ther 5:463-76. 2005
    ....
  56. ncbi Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation
    Chiara Casati
    Unit of Immunotherapy of Human Tumor, Fondazione Instituto di Ricerca e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milano, Italy
    J Immunol 180:3782-8. 2008
    ..Altogether, these data show for the first time a role of LAG-3 in mediating dendritic cell activation when expressed on the T cell surface or released after specific Ag stimulation in the interspaces of immunological synapses...
  57. ncbi International meeting "Immunotherapy of cancer: challenges and needs"
    Maria Ferrantini
    Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Cancer Immunol Immunother 56:581-5. 2007
    ....
  58. ncbi Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group
    Alessandro Testori
    Istituto Europeo di Oncologia, Milan, Italy
    J Clin Oncol 26:955-62. 2008
    ....
  59. ncbi The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward
    Michele Maio
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    J Transl Med 6:8. 2008
    ..Here, we report the main issues discussed during the meeting...
  60. ncbi NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients
    Cristina Maccalli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 13:7459-68. 2007
    ..The role of NKG2D receptor in antitumor immunosurveillance has not been completely clarified. We addressed this issue by investigating the involvement of this receptor in tumor-specific immunologic response in melanoma patients...
  61. ncbi Universal and stemness-related tumor antigens: potential use in cancer immunotherapy
    Giorgio Parmiani
    Department of Oncology, San Raffaele Scientific Institute, Italy
    Clin Cancer Res 13:5675-9. 2007
  62. ncbi The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level
    Michele Maio
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Tumori 94:179-81. 2008
    ..This article briefly summarizes the history and objectives of NIBIT, along with the actions so far taken by the Network...
  63. ncbi Interleukin-12: biological properties and clinical application
    Michele Del Vecchio
    Medical Oncology Unit 2, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy
    Clin Cancer Res 13:4677-85. 2007
    ..More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients...
  64. ncbi Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors and Unit of Medical Statistics and Biometry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 25:2546-53. 2007
    ....
  65. ncbi Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide
    Manuela Iero
    Unit of Immunotherapy of Human Tumors, IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy
    Cancer Immunol Immunother 56:1979-91. 2007
    ....
  66. ncbi Vaccination therapy in prostate cancer
    Andrea Marrari
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 56:429-45. 2007
    ..In some cases clinical responses were achieved showing that vaccine-primed T cells induced anti-tumour activity in vivo. The present findings and perspectives of the immunologic interventions in PC patients will be discussed...
  67. ncbi Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines
    Andrea Anichini
    Human Tumor Immunobiology and Tumor Immunotherapy Units, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 171:2134-41. 2003
    ....
  68. ncbi Melanoma immunology: past, present and future
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori Foundation, Milan, Italy
    Curr Opin Oncol 19:121-7. 2007
    ..This paper aims to evaluate the last three decades of research in melanoma immunotherapy and to provide insights in the future of this strategy...
  69. ncbi A clinical development paradigm for cancer vaccines and related biologics
    Axel Hoos
    Bristol Myers Squibb, Global Clinical Research, Oncology, Wallingford, CT 06492, USA
    J Immunother 30:1-15. 2007
    ..In addition, this report addresses clinical development challenges and issues for combination therapies...
  70. ncbi Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells
    Piero Dalerba
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:2321-9. 2005
    ..Taken together, our data show that, in a least subset of CRC, biochemical pathways involved in maintenance of telomere length, such as telomerase, are not activated in a constitutive way in all tumor cells...
  71. ncbi Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype
    Marialuisa Sensi
    Units of Immunobiology of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy
    Cancer Res 65:632-40. 2005
    ....
  72. ncbi Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer
    Vincenzo Mazzaferro
    Units of Hepatobiliary and Gastro Pancreatic Surgery, Istituto Nazionale per lo Studio e la Cura Tumori, 20133 Milan, Italy
    Clin Cancer Res 9:3235-45. 2003
    ..Feasibility, safety, and possible clinical benefits were also evaluated...
  73. ncbi Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma
    Roberto Luksch
    Department of Medical Oncology, Pediatric Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 89:263-8. 2003
    ..An additional aim was to assess whether any correlation between the immune modifications and the clinical outcome could be found...
  74. ncbi The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients
    Chiara Casati
    Unit of Immunotherapy of Human Tumors, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Cancer Res 63:4507-15. 2003
    ..These findings indicate that survivin could be considered a valuable tumor-associated antigen for immune-based clinical approaches in colorectal cancer...
  75. ncbi NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity
    Cristina Maccalli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via Venezian 1, I-20133 Milan, Italy
    Eur J Immunol 33:2033-43. 2003
    ..Taken together these data indicate that the engagement of NKG2D, depending on the expression of its ligands by target cells, can influence the pattern of anti-tumor reactivity by T lymphocytes...
  76. ncbi Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen
    Luisa Novellino
    Unit of Immunotherapy of Human Tumors and Unit of Molecular Mechanisms of Tumor Growth and Progression, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 170:6363-70. 2003
    ..These findings further support the relevance of CD4(+) T cells directed against mutated epitopes in tumor immunity and provide the rationale for a possible usage of mutated, tumor-specific Ags for immunotherapy of human cancer...
  77. ncbi Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells
    Venkatesh Ramakrishna
    Upstate Inc, Charlottesville, VA 22903, USA
    Int Immunol 15:751-63. 2003
    ..These findings broaden the list of CTL-defined antigens that could lead to the development of multi-epitope vaccines for the treatment of ovarian cancer...
  78. ncbi Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma
    Roberta Mortarini
    Human Tumors Immunobiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, 20133, Italy
    Cancer Res 63:2535-45. 2003
    ....
  79. ncbi Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues
    Matteo G Carrabba
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, 20133 Milan, Italy
    Cancer Res 63:1560-7. 2003
    ....
  80. ncbi Vaccine therapy of cancer
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, National Cancer Institute, Milan, Italy
    Suppl Tumori 1:S28. 2002
  81. ncbi Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice
    Francesco Lozupone
    Laboratory of Immunology, Istituto Superiore di Sanit, Rome, Italy
    Eur J Immunol 33:556-66. 2003
    ..Furthermore, this work shows that human tumors/SCID mouse models may be useful in evaluating the in vivo efficacy of adoptive immunotherapies...
  82. ncbi Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
    Licia Rivoltini
    Units of Human Tumor Immunotherapy and Immunobiology, Istituto Nazionale Tumori, Milan, Italy
    Immunol Rev 188:97-113. 2002
    ..Finally, we discuss the role of inducible nitric oxide synthases in determining the inhibition of apoptosis in melanoma cells, which can make such tumor cells resistant to the T-cell attack...
  83. ncbi Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
    Filiberto Belli
    Unit of General Surgery 2, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 20:4169-80. 2002
    ..CONCLUSION: Vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible and devoid of significant toxicity. This vaccine induced clinical and tumor-specific T-cell responses in a significant minority of patients...
  84. ncbi Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function
    Paola Matarrese
    Department of Ultrastructures, Istituto Superiore di Sanit, Rome Italy
    Am J Pathol 160:1507-20. 2002
    ....
  85. ncbi Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine
    Marilisa Carsana
    Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Gene Ther 9:243-53. 2002
    ..These results provide evidence for immunological changes, including in situ clonally expanded T cells, in metastases of patients vaccinated with IL-7 gene-transduced cells...
  86. ncbi Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells
    Licia Rivoltini
    Unit of Immunotherapy of Human Tumor, Gastrointestinal and Liver Surgery Unit, and Colorectal Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 171:3467-74. 2003
    ....
  87. ncbi Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial
    Massimo Di Nicola
    Cristina Gandini Bone Marrow Transplantation Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan I-20133, Italy
    Hum Gene Ther 14:1347-60. 2003
  88. ncbi Heat shock proteins and their use as anticancer vaccines
    Giorgio Parmiani
    Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 10:8142-6. 2004
  89. ncbi Tumor-infiltrating T cells--friend or foe of neoplastic cells?
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan
    N Engl J Med 353:2640-1. 2005
  90. ncbi International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
    Filippo Belardelli
    Istituto Superiore di Sanita, Rome, Italy
    Cancer Res 64:6827-30. 2004
    ..An entire session was devoted to the use of dendritic cells for the development of cancer vaccines. The results of clinical studies and the advantages of using new modalities for preparing dendritic cell-based vaccines were discussed...
  91. ncbi Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma
    Massimo Di Nicola
    Cristina Gandini Bone Marrow Transplantation Unit, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 10:5381-90. 2004
    ....
  92. ncbi A listing of human tumor antigens recognized by T cells: March 2004 update
    Luisa Novellino
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 54:187-207. 2005
    ..Overall, the updated list is a database tool for clinicians, scientists and students who have an interest in the field of tumor immunology and immunotherapy...
  93. ncbi Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells
    Michele Maio
    Cancer Bioimmunotherapy Unit and Division of Anesthesia, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, via Pedemontana Occ le, 12, Aviano, 33081 Italy
    Cancer Immunol Immunother 51:9-14. 2002
    ....
  94. ncbi Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens
    Diego Tosi
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    J Immunol 172:5363-70. 2004
    ..Together, our data suggest that the ability of IFN-DCs to efficiently prime anti-tumor CD8(+) T lymphocytes relied mostly on the positive cross-talk occurring between DCs and NK cells upon stimulation with IFN-alpha...
  95. ncbi Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice
    Francesco Lozupone
    Laboratories of Immunology and Virology, Istituto Superiore di Sanit, Rome, Italy
    Cancer Res 64:378-85. 2004
    ..Moreover, our study emphasizes the usefulness of human tumor/SCID mouse models for preclinical evaluation of immunotherapy protocols against human tumors...
  96. ncbi Immunotherapy of melanoma
    Giorgio Parmiani
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian, 1 20133 Milan, Italy
    Semin Cancer Biol 13:391-400. 2003
    ..or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma...
  97. ncbi Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen
    Monica Rodolfo
    Units of Melanoma Genetics, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy
    Cancer Res 63:6948-55. 2003
    ..We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy...
  98. ncbi Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer
    Chiara Castelli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
    Cancer Immunol Immunother 53:227-33. 2004
    ..The immunological properties of these proteins and their implications for vaccine in human cancer will be discussed. Immunological and clinical data of phase I/II studies in melanoma and colorectal cancer patients will be reviewed...
  99. ncbi T cell infiltration and prognosis in HCC patients
    Giorgio Parmiani
    J Hepatol 45:178-81. 2006
  100. ncbi Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells
    Luana Lugini
    Department of Drug Research and Evaluation, Istituto Superiore di Sanit, Viale Regina Elena 299, 00161 Rome, Italy
    Cancer Res 66:3629-38. 2006
    ..Moreover, our data suggest that cannibalism may represent a sort of "feeding" activity aimed at sustaining survival and progression of malignant tumor cells in an unfavorable microenvironment...
  101. ncbi CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma
    Viviana Vallacchi
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 68:715-23. 2008
    ..Together, these data indicate a role for CCN3 in melanoma cell interaction with the ECM by regulating integrin expression, resulting in altered cell adhesion and leading melanoma progression to aggressive disease...